1. Near-term launch of three new APIs Partial - In the Q4 FY25 announcement, management stated plans to accelerate growth through near-term launch of three new APIs. The anaesthetic API was launched in Q4 FY26, and Ketamine Hydrochloride API was launched earlier, with annual demand of over 200 tons; no disclosure in our record confirms the third near-term API launch.
2. FY27 API capex plan - ₹63 Cr Pending - At the Q3 FY26 PPT, management set an FY27 API capex plan of ₹63 Cr: New Production Block + 2 Clean Rooms ₹45 Cr, New Clean Room Facility ₹12 Cr, New Storage Area ₹6 Cr. FY26 balance sheet shows CWIP of ₹25.42 cr, up from ₹5.38 cr in FY25; no FY27 capex actuals are yet disclosed in our record, as FY27 is the current year.
3. API product selection - double-digit market share and \~50% gross margins Delivered - At the Q3 FY26 PPT, management stated the API product selection framework aims for double-digit market share in small-to-mid size molecules and \~50% gross margins, restated in Q1 FY27 PPT and Q2 FY26 materials. Q3 FY26 gross margin was 57.76% and FY26 gross margin 57.6%, with global market shares of Metformin \~10-11%, Sertraline \~30% and Tramadol \~11%; Q1 FY27 gross margin contracted to 52.5%.
4. Borrowing cost reduction - from 22.5% to 12.5%, with further reduction in coming years Delivered - At the Q3 FY26 PPT, management stated debt refinancing reduced borrowing cost from 22.5% to 12.5% effective 1 March 2025, with scope for further reduction in coming years, restated in the Q1 FY27 PPT. FY26 finance cost was ₹29.98 crore, down 19% YoY, and the Q1 FY27 announcement states management expects a reduction in finance costs from Q2 FY27 onwards given borrowings have been refinanced at a lower interest rate.
5. Debt/EBITDA leverage - moderate \~2X Delivered - At the Q3 FY26 PPT, management guided a moderate leverage ratio of \~2X Debt/EBITDA via refinanced debt and healthy internal accruals, restated in the Q1 FY27 PPT. FY26 balance sheet shows long-term borrowings ₹147.15 cr and short-term borrowings ₹68.30 cr, implying gross debt of ₹215.45 cr against FY26 EBITDA of ₹107.69 cr, or approximately 2.0X.
6. Four new API molecule commercialisations per year - beginning FY27 On track - At the Q3 FY26 PPT, management guided a pipeline of 4 new API molecule commercialisations each year beginning FY27, restated in Q1 FY27 PPT and Q2 FY26 materials. The Q1 FY27 PPT lists planned regulatory filings for Quetiapine Fumarate (US & CEP), Ketamine HCl (CEP) and Paroxetine HCl (Brazil, Korea); no FY27 commercialisation count is yet disclosed in our record.
7. Anaesthetic API launch - Q4 FY26 Delivered - At the Q3 FY26 PPT, management guided launch of an Anaesthetic (new API molecule) in Q4 FY26, with commercialisation in Q4 FY26. The new Anaesthetic API was launched with commercial dispatches beginning February 2026, with the new production block commissioned at Tanuku and first commercial shipment dispatched to a European customer.
8. Formulations sustainable profitability - FY27 onwards Pending - At the Q3 FY26 PPT, management guided delivery of sustainable profitability in Formulations from FY27 onwards, through scaling top brands, launching new therapies, and increasing front-line doctor engagement, restated in Q2 FY26 materials and Q1 FY27 PPT. FY26 Formulations revenue was ₹76 crore, up 7%, and Q1 FY27 company-level EBITDA margin contracted to 10.0% from 15.2% YoY; no Formulations-specific profitability read for Q1 FY27 is disclosed in our record.
9. Formulations break-even - FY26 Delivered - At the Q3 FY26 PPT, management guided the Formulations business to achieve profitability break-even in FY26 through better scale and cost-management efforts, restated in the Q2 FY26 PPT and related announcement. Formulations delivered financial break-even in 9MFY26, and the Q1 FY27 PPT confirms "envisaged break-even profitability in Formulations business delivered - financial break-even in FY26", with FY26 Formulations revenue of ₹76 crore, up 7%.
10. Three-year 11% CAGR target - FY22 Annual Report Missed - In the FY22 Annual Report, the company targeted an overall compounded annual growth rate of 11% over the next three years, driven by existing products, new product introductions, new divisions and markets, geographic spread, and expansion of manufacturing and research capacities. Revenue moved from ₹511 cr in FY22 to ₹500 cr in FY23, ₹576 cr in FY24 and ₹600 cr in FY25, a three-year CAGR of approximately 5.5%, with FY23 revenue declining 2.26%.
11. Dextromethorphan API commercialisation - FY2022 Missed - In the FY22 Annual Report, Dextromethorphan API (cough suppressant) was slated to be commercialised in FY2022, the same commitment having appeared in the FY21 Annual Report. Our record holds no disclosure confirming commercialisation in FY2022 or later; the API portfolio as of Q3 FY26 is described as 6 existing molecules plus 1 recent anaesthetic addition, with Dextromethorphan not named.
12. Sertraline capacity expansion - +40% in due course of time Partial - In the FY22 Annual Report, the company stated plans to further increase Sertraline capacity by about 40% "in due course of time", following the 50% expansion operational by end March 2021, restated in the FY21 Annual Report; the earlier FY20 Annual Report version targeted the 40% increase in FY2021. FY24 Sertraline API grew 33% in value and 39% in volume and FY25 grew 15% in value and 14% in volume, while the Q3 FY26 PPT notes a capacity ramp-up of +20% over the last 3 years via de-bottlenecking; no disclosure confirms completion of the full 40% expansion as originally framed.